Life Sciences Tools and Services

BOJI CRO

BOJI CRO released FY2026 Q1 earnings on April 24 Pre-Market (BJT), actual revenue CNY 220.16 M, actual EPS CNY 0.043

BOJI CRO released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 284.33 M, actual EPS CNY 0.0222

BOJI CRO released FY2025 Annual Earnings on April 24 After-Market (BJT), actual revenue CNY 868.64 M (forecast CNY 932 M), actual EPS CNY 0.0794 (forecast CNY 0.26)

BOJI CRO to Release FY2025 Earnings on April 25 After-Market (BJT), Forecast Revenue CNY 932 M, EPS CNY 0.26

BOJI CRO to Release FY2026 Q1 Earnings Report on April 25 Pre-Market BJT

BOJI CRO released FY2025 9 Months earnings on October 28 After-Market (BJT), actual revenue CNY 584.32M, actual EPS CNY 0.0569

BOJI CRO released FY2025 Q3 earnings on October 28 After-Market (BJT), actual revenue CNY 222.87 M, actual EPS CNY 0.0164

BOJI CRO FY2025 Q3 Earnings Release on October 29, 2025, After-Market (BJT)

BOJI CRO released FY2025 Q2 earnings on August 26 During-Market (BJT), actual revenue CNY 222.59 M, actual EPS CNY 0.0303

BOJI CRO released FY2025 Semi-Annual earnings on August 26 During-Market (BJT), actual revenue CNY 361.45 M, actual EPS CNY 0.0406

BOJI CRO to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Bio-Health Medical Subsidiaries Provide Clinical Trial Services

Boji Medical Receives CCC ESG Rating from Huazheng Index

Boji Medical Subsidiary Obtains Two Biopharmaceutical Patents

BioTech Medical Pharma's Self-developed Project Transfer Progress and Medical Device Business Development

Boji Medicine Continues BNCT Research

Boji Medical Uses DeepSeek to Enhance Drug R&D Efficiency

Biojet Medicine Participates in Clinical Research for Diabetes Mellitus Type 2 Combined with ED

Bio0Medicine Secretary Comments on Contract Cancellation and Stock Performance

Boji Pharmaceutical Net Profit Down 76.38% in Q1 2025

301230

301333

000516

300404

688246

AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%

Wallstreetcn

R&G Pharma

IMIC

GOODWILL

BOJI CRO released its Q3 2025 report, with operating revenue for the first three quarters at 584 million yuan, a year-on-year increase of 5.06%. The net profit attributable to the parent company was 21.9139 million yuan, a year-on-year decrease of 49.36%; the net profit after deducting non-recurring gains and losses was 14.9812 million yuan, a year-on-year decrease of 57.06%. The basic earnings per share were 0.0571 yuan

Zhitong

BOJI CRO released its performance for the first three quarters, with a net profit attributable to the parent company of 21.9139 million yuan, a decrease of 49.36%

BOJI CRO's subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., has obtained the "Drug Registration Certificate" issued by the National Medical Products Administration, approving its production of "Compound Polyethylene Glycol Electrolyte Powder." This drug is used for bowel cleansing prior to endoscopic or radiographic examinations and colon surgeries, with an expected sales scale of approximately RMB 220 million in public hospitals in China in 2024

BOJI CRO: Subsidiary Guangzhou Huasheng Pharmaceutical has obtained a drug registration certificate

603207

Xiao Fang Pharma and BOJI CRO signed a technical entrustment contract, in which BOJI CRO will assist in completing the clinical research and registration of the traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture." This cooperation marks an important progress for Xiao Fang Pharma in the field of innovative drugs, as both parties will leverage their respective advantages to enhance R&D efficiency and lay the foundation for product launch

Xiao Fang Pharma

Xiao Fang Pharma entrusts BOJI CRO to develop traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture" (indication for hair loss)

BOJI CRO recently obtained an invention patent issued by the National Intellectual Property Administration, with the patent name "A Method for Determining Gallic Acid in Berberine," certificate number 8272934, patent number ZL202510318197.1. This method has good separation effects in the field of drug component detection, with a short detection time and high resolution. Although it has little impact on the company's operating performance, it helps with technological innovation and enhances core competitiveness

BOJI CRO obtained an invention patent for the "Method for Determining Gallic Acid in Berberine."

BOJI CRO recently announced that its application for "FCZR" has received the clinical trial approval notice from the National Medical Products Administration. FCZR is a modified new drug targeting ear fungal disease, with significant clinical advantages. The drug's formulation and administration method have been optimized for ear drop application, allowing it to directly act on the ear canal lesions. Currently, there are no similar drugs approved for marketing domestically or internationally

BOJI CRO: "FCZR" has received the drug clinical trial approval notice

BOJI CRO announced that its controlling shareholder Wang Tingchun and the concerted party Fermi No. 13 plan to reduce their holdings by a total of no more than 11.4865 million shares, accounting for 3.00%, through block trades or centralized bidding from September 12, 2025, to December 11, 2025. Among them, Fermi No. 13 plans to reduce 1.7079 million shares through block trades and 3.8288 million shares through centralized bidding, while Wang Tingchun plans to reduce 5.9498 million shares through block trades

BOJI CRO: The controlling shareholder plans to reduce its holdings by 3.00% within three months

The medical services sector has seen a short-term decline, with BOJI CRO falling over 6%, followed by Nanmo Biology, Zhaoyan New Drug, Ruizhi Medicine, Sanbo Neuroscience, and others

The medical services sector has seen a short-term decline, with BOJI CRO falling over 6%

603087

The concept of weight loss drugs is fluctuating upward, with BOJI CRO and Gan & Lee hitting the daily limit, while Aorite, Deyuan Pharmaceutical, and Menohua are also rising

Gan & Lee

The concept of weight loss drugs fluctuates upward, with BOJI CRO and others hitting the limit up

688202

688222

300683

300149

688621

On July 17th, CRO concept stocks performed actively. As of 14:26, Medicilon rose nearly 18%, HitGen had previously hit the limit up, HITECK and BOJI CRO rose over 10%, while ChemPartner, Sun-Novo, and Hongbo Pharmaceutical rose over 5%

BOJI CRO(300404.SZ)